Gerson R, Tellez Bernal E, Lazaro Leon M, Sanchez Forgach E, Garcia Irigoyen C, Gutierrez Godinez F, Garcia Gonzalez H
Department of Medicine, Hospital General de Mexico, D. F.
Am J Clin Oncol. 1993 Aug;16(4):323-6. doi: 10.1097/00000421-199308000-00009.
Bleomycin is a powerful antitumoral antibiotic whose utilization has been limited by pulmonary toxicity. At the Medical Oncology Department of the Hospital General de Mexico, SS, 17 patients with high-risk testicular cancer were treated with therapeutic regimens based on cisplatin and bleomycin in continuous infusion. The mean bleomycin dose was 813 mg. Adequate renal function was observed in all patients during and after chemotherapy. During a minimum 4-year follow-up period, no patient experienced pulmonary toxicity; 3 patients died due to tumoral progression. The remaining 14 patients are alive and none of them had shown x-ray abnormalities nor a significant reduction in pulmonary vital capacity (PVC) or carbon monoxide diffusion capacity (DLCO). Bleomycin in continuous infusion can be an appropriate alternative for reducing pulmonary toxic effects. Therefore, randomized controlled studies should be conducted in order to determine if this treatment regime could enhance the therapeutic index.
博来霉素是一种强效抗肿瘤抗生素，但其应用因肺毒性而受到限制。在墨西哥总医院医学肿瘤学部门，17例高危睾丸癌患者接受了基于顺铂和博来霉素持续输注的治疗方案。博来霉素的平均剂量为813毫克。化疗期间及化疗后所有患者肾功能均正常。在至少4年的随访期内，无患者出现肺毒性；3例患者因肿瘤进展死亡。其余14例患者存活，且均未出现X线异常，肺肺活量（PVC）或一氧化碳弥散量（DLCO）也未显著降低。持续输注博来霉素可能是减少肺毒性作用的合适选择。因此，应进行随机对照研究以确定该治疗方案是否能提高治疗指数。
